The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Circulating miRNAs are correlated with tumor progression in prostate cancer
Open accessAbstract
Circulating miRNAs have recently been indicated as practicable and promising biomarkers for noninvasive diagnosis in various tumor entities. However, cell‐free miRNAs have not been found to correlate with clinicopathological variables in epithelial carcinomas. To learn more about the potential clinical relevance of circulating miRNAs in prostate cancer, we screened 667 miRNAs in serum samples from patients with metastatic (n= 7) and localized prostate cancer (n= 14). Various miRNAs were highly abundant in the sera of patients with metastatic disease, and five upregulated miRNAs (miRNA‐375, miRNA‐9*, miRNA‐141, miRNA‐200b and miRNA‐516a‐3p) were selected for further validation. In the first validation study (n= 45), selected miRNAs were analyzed in a prospectively collected serum set taken from different prostate cancer risk groups. Most of the selected miRNAs were significantly correlated with adverse risk factors when different clinicopathological variables were analyzed. Circulating miRNA‐375 and miRNA‐141 turned out to be the most pronounced markers for high‐risk tumors. Their levels also correlated with high Gleason score or lymph‐node positive status in a second independent validation study (n= 71). In addition, the expression levels of miRNA‐375 and miRNA‐141 were monitored in 72 prostate tissue samples (36 tumor vs. 36 benign). Both miRNAs were highly expressed in all samples and significantly upregulated in the tumors compared to normal tissues. Overall, our observations suggest that miRNA‐375 and miRNA‐141 expression is enhanced in prostate cancer specimens and their release into the blood is further associated with advanced cancer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer
Taylor, D. D., & Gercel-Taylor, C. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.04.033 · Cited by 2,288
RetractedControlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
Skog, J., Würdinger, T., van Rijn, S., Meijer, D. H., Gainche, L., Curry, W. T., Carter, B. S., Krichevsky, A. M., & Breakefield, X. O. (2008) · Nature Cell Biology · doi:10.1038/ncb1800 · Cited by 5,001
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
Bushati, N., & Cohen, S. M. (2007) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.23.090506.123406 · Cited by 2,750
Cited by
Cancer biomarker detection: recent achievements and challenges
Wu, L., & Qu, X. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00370e · Cited by 1,214
Clinical relevance of circulating cell-free microRNAs in cancer
Schwarzenbach, H., Nishida, N., Calin, G. A., & Pantel, K. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.5 · Cited by 969
Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879
Grange, C., Tapparo, M., Collino, F., Vitillo, L., Damasco, C., Deregibus, M. C., Tetta, C., Bussolati, B., & Camussi, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0241 · Cited by 851
Changes in circulating microRNA levels associated with prostate cancer
Bryant, R. J., Pawlowski, T., Catto, J. W. F., Marsden, G., Vessella, R. L., Rhees, B., Kuslich, C., Visakorpi, T., & Hamdy, F. C. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.595 · Cited by 715
Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
Huang, X., Yuan, T., Liang, M., Du, M., Xia, S., Dittmar, R., Wang, D., See, W., Costello, B. A., Quevedo, F., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.035 · Cited by 681
Exosomes and tumor-mediated immune suppression
Whiteside, T. L. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81136 · Cited by 569
Exosomes: Novel Biomarkers for Clinical Diagnosis
Lin, J., Li, J., Huang, B., Liu, J., Chen, X., Chen, X.-M., Xu, Y.-M., Huang, L.-F., & Wang, X.-Z. (2015) · The Scientific World Journal · doi:10.1155/2015/657086 · Cited by 562
Boriachek, K., Islam, M. N., Möller, A., Salomon, C., Nguyen, N., Hossain, M. S. A., Yamauchi, Y., & Shiddiky, M. J. A. (2018) · Small · doi:10.1002/smll.201702153 · Cited by 495
MicroRNA in Prostate, Bladder, and Kidney Cancer: A Systematic Review
Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., Hamdy, F. C., Kallioniemi, O., Mengual, L., Schlomm, T., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.01.044 · Cited by 469
Self-citationSerum microRNAs as non-invasive biomarkers for cancer
Brase, J. C., Wuttig, D., Kuner, R., & Sültmann, H. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-306 · Cited by 421
Self-citationCirculating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review)
ALLEGRA, A., ALONCI, A., CAMPO, S., PENNA, G., PETRUNGARO, A., GERACE, D., & MUSOLINO, C. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1647 · Cited by 359
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., Li, H., Zhu, X., Yao, L., & Zhang, J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3037-0 · Cited by 354
Humphries, B., & Yang, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3052 · Cited by 346
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer
Yaman Agaoglu, F., Kovancilar, M., Dizdar, Y., Darendeliler, E., Holdenrieder, S., Dalay, N., & Gezer, U. (2011) · Tumor Biology · doi:10.1007/s13277-011-0154-9 · Cited by 341
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
Cheng, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.001 · Cited by 334
MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges
Lan, H., Lu, H., Wang, X., & Jin, H. (2015) · BioMed Research International · doi:10.1155/2015/125094 · Cited by 330
The Potential of MicroRNAs as Prostate Cancer Biomarkers
Fabris, L., Ceder, Y., Chinnaiyan, A. M., Jenster, G. W., Sorensen, K. D., Tomlins, S., Visakorpi, T., & Calin, G. A. (2016) · European Urology · doi:10.1016/j.eururo.2015.12.054 · Cited by 311
The emerging role of extracellular vesicles as biomarkers for urogenital cancers
Nawaz, M., Camussi, G., Valadi, H., Nazarenko, I., Ekström, K., Wang, X., Principe, S., Shah, N., Ashraf, N. M., Fatima, F., et al. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.301 · Cited by 294
Endzeliņš, E., Berger, A., Melne, V., Bajo-Santos, C., Soboļevska, K., Ābols, A., Rodriguez, M., Šantare, D., Rudņickiha, A., Lietuvietis, V., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3737-z · Cited by 266
Circulating microRNAs in plasma as early detection markers for breast cancer
Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S., Turchinovich, A., Arlt, D., Rath, M., Sohn, C., Benner, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.27799 · Cited by 266
Small RNAs have a large impact: Circulating microRNAs as biomarkers for human diseases
Weiland, M., Gao, X.-H., Zhou, L., & Mi, Q.-S. (2012) · RNA Biology · doi:10.4161/rna.20378 · Cited by 265
U6 is not a suitable endogenous control for the quantification of circulating microRNAs
Xiang, M., Zeng, Y., Yang, R., Xu, H., Chen, Z., Zhong, J., Xie, H., Xu, Y., & Zeng, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.10.064 · Cited by 259
Distinct AGO1 and AGO2 associated miRNA profiles in human cells and blood plasma
Turchinovich, A., & Burwinkel, B. (2012) · RNA Biology · doi:10.4161/rna.21083 · Cited by 199
Circulating inflammatory miRNA signature in response to different doses of aerobic exercise
de Gonzalo-Calvo, D., Dávalos, A., Montero, A., García-González, Á., Tyshkovska, I., González-Medina, A., Soares, S. M. A., Martínez-Camblor, P., Casas-Agustench, P., Rabadán, M., et al. (2015) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00077.2015 · Cited by 150
Profiling of circulating microRNAs for prostate cancer biomarker discovery
Haldrup, C., Kosaka, N., Ochiya, T., Borre, M., Høyer, S., Orntoft, T. F., & Sorensen, K. D. (2014) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0169-4 · Cited by 83
Soliman, H. M., Ghonaim, G. A., Gharib, S. M., Chopra, H., Farag, A. K., Hassanin, M. H., Nagah, A., Emad-Eldin, M., Hashem, N. E., Yahya, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910794 · Cited by 81
Circulating microRNAs as Promising Tumor Biomarkers
(2014) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2014.09.007 · Cited by 40
Metadata
- Authors
- Brase, J. C., Johannes, M., Schlomm, T., Fälth, M., Haese, A., Steuber, T., Beissbarth, T., Kuner, R., & Sültmann, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2010-11-27
- Volume
- 128
- Issue
- 3
- Pages
- 608-616
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2022667041
- Cited by
- 587
- References
- 27
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.